CoChat
Sign Up
Cited by 234Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration MechanismsTelomeres, Telomerase, and Senescence

The DOI matches its Crossref record; 109 of the 109 references it cites were found in a registry or an index.

Tau oligomer induced HMGB1 release contributes to cellular senescence and neuropathology linked to Alzheimer’s disease and frontotemporal dementia

Open access
Gaikwad, Sagar, Puangmalai, Nicha, Bittar, Alice, Montalbano, Mauro, Garcia, Stephanie, McAllen, Salome, Bhatt, Nemil, Sonawane, Minal, Sengupta, Urmi, Kayed, Rakez·2021·Cell Reports
DOI 10.1016/j.celrep.2021.109419PMC PMC8341760
Open this paper in CoChat — free accountOpen PDF

Abstract

Aging, pathological tau oligomers (TauO), and chronic inflammation in the brain play a central role in tauopathies, including Alzheimer's disease (AD) and frontotemporal dementia (FTD). However, the underlying mechanism of TauO-induced aging-related neuroinflammation remains unclear. Here, we show that TauO-associated astrocytes display a senescence-like phenotype in the brains of patients with AD and FTD. TauO exposure triggers astrocyte senescence through high mobility group box 1 (HMGB1) release and inflammatory senescence-associated secretory phenotype (SASP), which mediates paracrine senescence in adjacent cells. HMGB1 release inhibition using ethyl pyruvate (EP) and glycyrrhizic acid (GA) prevents TauO-induced senescence through inhibition of p38-mitogen-activated protein kinase (MAPK) and nuclear factor κB (NF-κB)-the essential signaling pathways for SASP development. Despite the developed tauopathy in 12-month-old hTau mice, EP+GA treatment significantly decreases TauO and senescent cell loads in the brain, reduces neuroinflammation, and thus ameliorates cognitive functions. Collectively, TauO-induced HMGB1 release promotes cellular senescence and neuropathology, which could represent an important common pathomechanism in tauopathies including AD and FTD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.celrep.2021.109419

Cites

109 of 109 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Astrocytes exhibiting a senescence-like phenotype are associated with TauO in the brain of patients with AD and FTD (A) Representative immunostaining showing GFAP (green), p16INK4A (red), and TauO (magenta) immunoreactivities and DAPI (blue nuclei) in sections of the frontal cortex from patients with AD and FTD and NDC subjects. In AD and FTD brains, triple immunostaining displays colocalization of p16INK4A and TauO immunoreactivities in GFAP-positive astrocytes. Only a small percentage of cells display p16INK4A and TauO in the NDC brain. Arrows indicate TauO-associated cells exhibiting p16INK4A and GFAP immunoreactivities in AD and FTD. (B and C) Percentage of p16INK4A-positive and GFAP-positive cells, and (C) average numbers of TauO inclusions per 500 μm2 (mean ± SEM; AD n = 8 cases, FTD n = 6 cases, and NDC n = 8 cases; minimum 6–8 images were analyzed from each section). One-way ANOVA followed by Tukey’s post hoc test was used to determine the statistical differences among the groups. Scale bars, 20 μm.
Figure 1. Astrocytes exhibiting a senescence-like phenotype are associated with TauO in the brain of patients with AD and FTD (A) Representative immunostaining showing GFAP (green), p16INK4A (red), and TauO (magenta) immunoreactivities and DAPI (blue nuclei) in sections of the frontal cortex from patients with AD and FTD and NDC subjects. In AD and FTD brains, triple immunostaining displays colocalization of p16INK4A and TauO immunoreactivities in GFAP-positive astrocytes. Only a small percentage of cells display p16INK4A and TauO in the NDC brain. Arrows indicate TauO-associated cells exhibiting p16INK4A and GFAP immunoreactivities in AD and FTD. (B and C) Percentage of p16INK4A-positive and GFAP-positive cells, and (C) average numbers of TauO inclusions per 500 μm2 (mean ± SEM; AD n = 8 cases, FTD n = 6 cases, and NDC n = 8 cases; minimum 6–8 images were analyzed from each section). One-way ANOVA followed by Tukey’s post hoc test was used to determine the statistical differences among the groups. Scale bars, 20 μm.CC BY-NC-ND · PubMed Central
Figure 2. Nucleo-cytoplasmic translocation and active release of HMGB1 is a hallmark of TauO-induced senescence phenotype in primary astrocytes (A–F) Upon stimulation with TauO or vehicle for 11 days, astrocytes were examined for HMGB1 translocation and release by immunostaining and flow cytometry analysis, respectively. Arrows point to TauO-induced translocation of HMGB1, a signature of cellular senescence. Scale bars, 50 μm. TauO exposure significantly increased p16INK4A-positive astrocytes (C), the percentage of SA-β-gal-positive astrocytes (D), and cell-cycle arrest (E) p16INK4A staining (F) after 4 days of treatment with or without conditional media (CM) from senescent astrocytes in the presence or absence of α-HMGB1 antibody (4 μg/mL). Representative images showing the relative decrease in number of p16INK4A-positive astrocytes after α-HMGB1 antibody treatment. Scale bar, 50 μm. Data are representative of at least three independent experiments (mean ± SEM). Statistical analyses were measured by unpaired, two-tailed Student’s t test.
Figure 2. Nucleo-cytoplasmic translocation and active release of HMGB1 is a hallmark of TauO-induced senescence phenotype in primary astrocytes (A–F) Upon stimulation with TauO or vehicle for 11 days, astrocytes were examined for HMGB1 translocation and release by immunostaining and flow cytometry analysis, respectively. Arrows point to TauO-induced translocation of HMGB1, a signature of cellular senescence. Scale bars, 50 μm. TauO exposure significantly increased p16INK4A-positive astrocytes (C), the percentage of SA-β-gal-positive astrocytes (D), and cell-cycle arrest (E) p16INK4A staining (F) after 4 days of treatment with or without conditional media (CM) from senescent astrocytes in the presence or absence of α-HMGB1 antibody (4 μg/mL). Representative images showing the relative decrease in number of p16INK4A-positive astrocytes after α-HMGB1 antibody treatment. Scale bar, 50 μm. Data are representative of at least three independent experiments (mean ± SEM). Statistical analyses were measured by unpaired, two-tailed Student’s t test.CC BY-NC-ND · PubMed Central
Figure 3. Inhibition of HMGB1 signaling effectively prevents TauO-induced senescence-like phenotype in cultured astrocytes Primary astrocytes were cultured in poly-L-lysine (PLL)-coated plates for 48 h and then pretreated with or without HMGB1 release inhibitors EP (10 mM) and/or GA (250 μM) for 30 min followed by treatment with TauO (0.5 μM) for 11 days. (A–C) HMGB1 release inhibition prevents TauO-induced astrocyte senescence, as shown by the decreased percentage of p16INK4A-positive cells and p16INK4A mean fluorescence intensity (MFI) and increased MFI of intracellular HMGB1 by flow cytometry. Representative graphs are shown from a minimum of three to four independent experiments (mean ± SEM). Statistical significance was determined by using one-way ANOVA followed by Tukey’s post hoc test (**p < 0.05; ***p < 0.0001). (D and E) Effect of EP+GA on relative protein levels of p16INK4A, HMGB1, and RAGE was measured by immunoblotting followed by densitometry quantification; β-actin was used as a loading control. The densitometry bar graph is numbered as in blots. Data are shown as mean ± SEM. Statistical significance was determined by using one-way ANOVA followed by Tukey’s post hoc test (**p < 0.05; ***p < 0.0001). (F) Effect of EP+GA on TauO-induced astrocyte senescence was measured by SA-β-gal staining. Pretreatment with EP (10 mM) + GA (250 μM) attenuated TauO-induced astrocytes senescence-like phenotype as shown by decreased SA-β-gal activity. Scale bar, 50 μm. Data are shown as mean ± SEM from four independent experiments in duplicates. Statistical significance was determined using unpaired, two-tailed Student’s t test. (G–I) Conditioned media from the astrocytes culture were used to measure secreted levels of HMGB1, (H) IL-6, and (I) TNF-α using ELISA showing HMGB1 inhibitors effectively inhibit TauO-induced SASP activity. Data are mean ± SEM from at least three independent experiments. Statistical analysis was performed by one-way ANOVA followed by Tukey’s post hoc test. (J) Phosphorylated protein levels of p38 and NF-κB assayed by immunoblotting, followed by densitometry quantification; GAPDH was used as a loading control. Data are shown as mean ± SEM (*p < 0.05; **p < 0.001; ***p < 0.0001).
Figure 3. Inhibition of HMGB1 signaling effectively prevents TauO-induced senescence-like phenotype in cultured astrocytes Primary astrocytes were cultured in poly-L-lysine (PLL)-coated plates for 48 h and then pretreated with or without HMGB1 release inhibitors EP (10 mM) and/or GA (250 μM) for 30 min followed by treatment with TauO (0.5 μM) for 11 days. (A–C) HMGB1 release inhibition prevents TauO-induced astrocyte senescence, as shown by the decreased percentage of p16INK4A-positive cells and p16INK4A mean fluorescence intensity (MFI) and increased MFI of intracellular HMGB1 by flow cytometry. Representative graphs are shown from a minimum of three to four independent experiments (mean ± SEM). Statistical significance was determined by using one-way ANOVA followed by Tukey’s post hoc test (**p < 0.05; ***p < 0.0001). (D and E) Effect of EP+GA on relative protein levels of p16INK4A, HMGB1, and RAGE was measured by immunoblotting followed by densitometry quantification; β-actin was used as a loading control. The densitometry bar graph is numbered as in blots. Data are shown as mean ± SEM. Statistical significance was determined by using one-way ANOVA followed by Tukey’s post hoc test (**p < 0.05; ***p < 0.0001). (F) Effect of EP+GA on TauO-induced astrocyte senescence was measured by SA-β-gal staining. Pretreatment with EP (10 mM) + GA (250 μM) attenuated TauO-induced astrocytes senescence-like phenotype as shown by decreased SA-β-gal activity. Scale bar, 50 μm. Data are shown as mean ± SEM from four independent experiments in duplicates. Statistical significance was determined using unpaired, two-tailed Student’s t test. (G–I) Conditioned media from the astrocytes culture were used to measure secreted levels of HMGB1, (H) IL-6, and (I) TNF-α using ELISA showing HMGB1 inhibitors effectively inhibit TauO-induced SASP activity. Data are mean ± SEM from at least three independent experiments. Statistical analysis was performed by one-way ANOVA followed by Tukey’s post hoc test. (J) Phosphorylated protein levels of p38 and NF-κB assayed by immunoblotting, followed by densitometry quantification; GAPDH was used as a loading control. Data are shown as mean ± SEM (*p < 0.05; **p < 0.001; ***p < 0.0001).CC BY-NC-ND · PubMed Central
Figure 4. Treatment with HMGB1 release inhibitors ameliorates tau pathology and cognitive decline in hTau mice (A) Experimental design for 8-week treatment with HMGB1 release inhibitors EP (80 mg/kg) + GA (20 mg/kg) or vehicle (saline) three times per week, beginning at 12 months of age in hTau mice. (B) Images of thioflavin-S staining and quantification of NFTs (tangles per region of interest) in the hippocampus. Scale bars, 200 μm. Data are shown as the mean ± SEM. (C) Representative immunostaining images showing hyperphosphorylated tau (AT8 immunoreactivities) in the hippocampus of hTau mice treated with either saline or EP+GA (scale bars, 50 μm) and quantification of AT8-positive cells per 500 μm2. Data are the mean ± SEM; unpaired, two-tailed Student’s t test was used to determine the statistical differences. (D) Novel-object recognition task was used to measure the impact of EP+GA treatment on memory in hTau mice. Mice treated with EP+GA show significantly higher discrimination index than vehicle-treated mice; heatmap of representative mice from the vehicle and EP+GA treatment group showing the time spent on exploring old or novel objects. Statistical significance was determined using unpaired, two-tailed Student’s t test. (E) Y-maze spontaneous alternation test: percentage of spontaneous alterations were measured before and after 8 weeks of EP+GA or vehicle treatment. Data are the mean ± SEM; unpaired, two-tailed Student’s t test was used to determine the statistical differences. (F) Immunostaining showing NeuN-positive neuronal cells in the CA3 pyramidal layer of the hippocampus of hTau mice treated with either vehicle or EP+GA. Scale bar, 100 μm. Data are the mean ± SEM; unpaired, two-tailed Student’s t test was used to determine the statistical differences.
Figure 4. Treatment with HMGB1 release inhibitors ameliorates tau pathology and cognitive decline in hTau mice (A) Experimental design for 8-week treatment with HMGB1 release inhibitors EP (80 mg/kg) + GA (20 mg/kg) or vehicle (saline) three times per week, beginning at 12 months of age in hTau mice. (B) Images of thioflavin-S staining and quantification of NFTs (tangles per region of interest) in the hippocampus. Scale bars, 200 μm. Data are shown as the mean ± SEM. (C) Representative immunostaining images showing hyperphosphorylated tau (AT8 immunoreactivities) in the hippocampus of hTau mice treated with either saline or EP+GA (scale bars, 50 μm) and quantification of AT8-positive cells per 500 μm2. Data are the mean ± SEM; unpaired, two-tailed Student’s t test was used to determine the statistical differences. (D) Novel-object recognition task was used to measure the impact of EP+GA treatment on memory in hTau mice. Mice treated with EP+GA show significantly higher discrimination index than vehicle-treated mice; heatmap of representative mice from the vehicle and EP+GA treatment group showing the time spent on exploring old or novel objects. Statistical significance was determined using unpaired, two-tailed Student’s t test. (E) Y-maze spontaneous alternation test: percentage of spontaneous alterations were measured before and after 8 weeks of EP+GA or vehicle treatment. Data are the mean ± SEM; unpaired, two-tailed Student’s t test was used to determine the statistical differences. (F) Immunostaining showing NeuN-positive neuronal cells in the CA3 pyramidal layer of the hippocampus of hTau mice treated with either vehicle or EP+GA. Scale bar, 100 μm. Data are the mean ± SEM; unpaired, two-tailed Student’s t test was used to determine the statistical differences.CC BY-NC-ND · PubMed Central
Figure 5. HMGB1 release inhibitors treatment modulates TauO-associated senescent cells in 12-month-old hTau mice (A) Representative immunostaining images and quantification of TauO-associated senescent astrocytes in the hippocampus. Representative immunostaining showing GFAP (green), p16INK4A (red), and TauO (magenta) immunoreactivities and DAPI (blue nuclei) in the hippocampus of hTau mice treated with either vehicle or EP+GA. Images display colocalization of p16INK4A and TauO in GFAP-positive astrocytes. (B–E) The graph showing quantitative analysis of p16INK4A area load (B), TauO area load (C), p16INK4A MFI (D), and percentage of p16INK4A-positive and GFAP-positive cells (E) in the hippocampus of hTau mice treated with vehicle (n = 5 mice) and EP+GA (n = 6 mice). Data are shown as mean ± SEM; unpaired, two-tailed Student’s t test was used to determine the statistical differences. Scale bars, 200 μm. (F–M) Immunostaining quantification of cytoplasmic HMGB1-positive cells (F and J), number of γH2AX foci (G and K), p16INK4A-positive cells (H and L), and IL-6-positive cells (I and M) in the cortex of hTau mice treated with vehicle (n = 5 mice) and EP+GA (n = 6 mice). Data are shown as mean ± SEM; unpaired, two-tailed Student’s t test was used to determine the statistical differences. Scale bar, 20 μm.
Figure 5. HMGB1 release inhibitors treatment modulates TauO-associated senescent cells in 12-month-old hTau mice (A) Representative immunostaining images and quantification of TauO-associated senescent astrocytes in the hippocampus. Representative immunostaining showing GFAP (green), p16INK4A (red), and TauO (magenta) immunoreactivities and DAPI (blue nuclei) in the hippocampus of hTau mice treated with either vehicle or EP+GA. Images display colocalization of p16INK4A and TauO in GFAP-positive astrocytes. (B–E) The graph showing quantitative analysis of p16INK4A area load (B), TauO area load (C), p16INK4A MFI (D), and percentage of p16INK4A-positive and GFAP-positive cells (E) in the hippocampus of hTau mice treated with vehicle (n = 5 mice) and EP+GA (n = 6 mice). Data are shown as mean ± SEM; unpaired, two-tailed Student’s t test was used to determine the statistical differences. Scale bars, 200 μm. (F–M) Immunostaining quantification of cytoplasmic HMGB1-positive cells (F and J), number of γH2AX foci (G and K), p16INK4A-positive cells (H and L), and IL-6-positive cells (I and M) in the cortex of hTau mice treated with vehicle (n = 5 mice) and EP+GA (n = 6 mice). Data are shown as mean ± SEM; unpaired, two-tailed Student’s t test was used to determine the statistical differences. Scale bar, 20 μm.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 109 references

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Gaikwad, S., Puangmalai, N., Bittar, A., Montalbano, M., Garcia, S., McAllen, S., Bhatt, N., Sonawane, M., Sengupta, U., & Kayed, R.
Affiliations
The University of Texas Medical Branch at Galveston (US)
Corresponding author
Kayed, Rakez
ORCID
Venue
Cell Reports
Publisher
Elsevier BV
Published
2021-07
Volume
36
Issue
3
Pages
109419
ISSN
2211-1247 (ISSN-L)
DOI
10.1016/j.celrep.2021.109419
PMC
PMC8341760
OpenAlex
W3186179545
Cited by
234
References
109
Citations by year
2026: 49 · 2025: 55 · 2024: 52 · 2023: 43 · 2022: 28 · 2021: 6
FWCI
20.24
Type
journal article
Language
en
Open access
Licence
Locations
  • Cell Reports (publishedVersion, cc-by-nc-nd)
  • SSRN Electronic Journal (acceptedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion, cc-by-nc-nd)
Funders
  • National Institutes of Health (R01AG054025, R01AG060718, R01NS094557, RFA1AG055771)
  • American Heart Association (17CSA33620007)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
Keywords
tau oligomers, HMGB1 release, cellular senescence, astrocytes, senescence-associated secretory phenotype, neuroinflammation, Alzheimer's disease, frontotemporal dementia, tauopathy, p38 MAPK, NF-κB, ethyl pyruvate, glycyrrhizin, paracrine senescence, cognitive function
MeSH terms
Alzheimer Disease, Animals, Astrocytes, Brain, Cell Nucleus, Cells, Cultured, Cognition Disorders, Humans, Mice, Inbred C57BL, Mice, Transgenic, Phenotype, Pyruvates, tau Proteins, Cellular Senescence, Glycyrrhizic Acid, Protein Transport, HMGB1 Protein, Mice, Frontotemporal Dementia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review